CAPRISA 008 was a two-arm, open-label, randomized controlled, non-inferiority implementation trial that provided participants from CAPRISA 004 with post-trial access to tenofovir gel while generating evidence that could be used for future implementation of topical pre-exposure prophylaxis (PrEP) among women. Its findings on the delivery of a microbicide containing tenofovir gel in family planning clinics are reported in this chapter of a book about HIV prevention and treatment trials conducted by the Centre for the AIDS Programme of Research in South Africa.